Coagulation studies in very low-birthweight infants

J H Seguin1, W H Topper

  • 1Kansas University Children's Center, Department of Pediatrics, University of Kansas Medical Center, Kansas City.

Insights

Establishing reference ranges for coagulation studies in premature infants (24-29 weeks gestational age) is crucial for managing bleeding disorders. This study provides vital prothrombin time, activated partial thromboplastin time, and fibrinogen data for very low-birthweight infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Hematology
  • Clinical Pathology

Background:

  • Premature infants, especially those with very low birth weight, often experience hemostatic disorders.
  • Accurate reference values for coagulation parameters in this population are essential for effective clinical management.
  • Existing reference ranges may not adequately represent the unique physiological state of extremely premature neonates.

Purpose of the Study:

  • To determine reference values for prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels in premature infants.
  • To establish normal coagulation ranges for infants born between 24 and 29 weeks' gestational age.
  • To facilitate comparison with adult reference ranges by converting infant values to ratios.

Main Methods:

  • Prospective data collection over a 4-year period from very low-birthweight infants admitted to a neonatal intensive care nursery.
  • Measurement of prothrombin time, activated partial thromboplastin time, and plasma fibrinogen levels.
  • Calculation of ratios of infant coagulation values to adult control values.

Main Results:

  • Fifty-two premature infants (24-29 weeks gestational age) were analyzed.
  • Mean PT was 14.5 seconds, mean aPTT was 69.5 seconds, and mean fibrinogen level was 1.35 g/L.
  • Ratio comparisons aided in standardizing results against established adult reference ranges.

Conclusions:

  • The study provides essential reference values for coagulation parameters in extremely premature infants.
  • These data are critical for the diagnosis and management of hemostatic disorders in this vulnerable patient group.
  • Normal ranges are needed for developing evidence-based protocols to prevent complications of abnormal coagulation in preterm neonates.